Takeda, Eli Lilly must defend racketeering suit over diabetes drug, judge rules

Lilly intends to appeal the ruling that the company defrauded payers for marketing a diabetes treatment without disclosing cancer risks.
Photo: Darron Cummings/AP/Ritzau Scanpix
Photo: Darron Cummings/AP/Ritzau Scanpix
By David Voreacos, bloomberg

A federal judge ruled Takeda Pharmaceutical Co. and Eli Lilly & Co. must defend a racketeering lawsuit claiming they defrauded third-party payers by marketing the Actos diabetes drug without disclosing its association with the risk of bladder cancer.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading